$VSTM
Verastem, Inc.

2024 Q1 Form 10-K Financial Statement

#000155837024003250 Filed on March 14, 2024

View on sec.gov

Income Statement

Concept 2024 Q1 2023 Q4 2023
Revenue $0.00 $0.00
YoY Change -100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $10.35M $8.637M $30.73M
YoY Change 41.25% 41.45% 23.04%
% of Gross Profit
Research & Development $17.71M $22.50M $61.36M
YoY Change 47.37% 109.52% 21.36%
% of Gross Profit
Depreciation & Amortization $6.000K $5.000K $100.0K
YoY Change -80.0% -82.76% 0.0%
% of Gross Profit
Operating Expenses $28.06M $31.14M $92.08M
YoY Change 45.05% 84.85% 21.91%
Operating Profit -$28.06M -$92.08M
YoY Change 45.05% 26.25%
Interest Expense $1.130M $749.0K $4.139M
YoY Change 46.94% 1564.44% 93.68%
% of Operating Profit
Other Income/Expense, Net -$30.00K $3.022M -$109.0K
YoY Change 328.57% -43271.43% -331.91%
Pretax Income -$27.37M -$87.37M
YoY Change 62.83% 18.36%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$33.86M -$27.37M -$87.37M
YoY Change 115.5% 62.83% 18.36%
Net Earnings / Revenue
Basic Earnings Per Share -$1.26 -$3.96
Diluted Earnings Per Share -$1.02 -$3.93
COMMON SHARES
Basic Shares Outstanding 25.30M 25.27M 22.05M
Diluted Shares Outstanding 22.05M

Balance Sheet

Concept 2024 Q1 2023 Q4 2023
SHORT-TERM ASSETS
Cash & Short-Term Investments $110.1M $137.1M $137.1M
YoY Change -0.97% 56.02% 56.02%
Cash & Equivalents $81.32M $77.91M $77.91M
Short-Term Investments $28.81M $59.22M $59.22M
Other Short-Term Assets $7.323M $6.553M $6.553M
YoY Change -4.76% 32.52% 32.52%
Inventory
Prepaid Expenses
Receivables $0.00 $0.00
Other Receivables $0.00 $0.00
Total Short-Term Assets $117.7M $143.7M $143.7M
YoY Change -1.03% 54.71% 54.71%
LONG-TERM ASSETS
Property, Plant & Equipment $52.00K $37.00K $1.208M
YoY Change -16.13% -59.78% -35.78%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $4.575M $4.587M $4.828M
YoY Change 12608.33% 7808.62% 1514.72%
Total Long-Term Assets $5.865M $6.036M $6.036M
YoY Change 195.61% 176.88% 176.88%
TOTAL ASSETS
Total Short-Term Assets $117.7M $143.7M $143.7M
Total Long-Term Assets $5.865M $6.036M $6.036M
Total Assets $123.5M $149.7M $149.7M
YoY Change 2.2% 57.51% 57.51%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $7.449M $7.184M $7.184M
YoY Change 51.93% 46.58% 46.58%
Accrued Expenses $17.38M $17.93M $18.87M
YoY Change 24.72% 19.66% 19.6%
Deferred Revenue
YoY Change
Short-Term Debt $911.0K $0.00 $0.00
YoY Change -9.26%
Long-Term Debt Due $0.00 $0.00
YoY Change -100.0% -100.0%
Total Short-Term Liabilities $26.73M $26.38M $26.38M
YoY Change 19.53% 21.77% 21.77%
LONG-TERM LIABILITIES
Long-Term Debt $40.12M $40.09M $40.09M
YoY Change 1.39% 63.44% 63.44%
Other Long-Term Liabilities $10.47M $4.719M $4.719M
YoY Change 119.96% 221.02% 221.02%
Total Long-Term Liabilities $50.59M $44.81M $44.81M
YoY Change 14.12% 72.35% 72.35%
TOTAL LIABILITIES
Total Short-Term Liabilities $26.73M $26.38M $26.38M
Total Long-Term Liabilities $50.59M $44.81M $44.81M
Total Liabilities $77.32M $71.19M $71.19M
YoY Change 15.93% 49.36% 49.36%
SHAREHOLDERS EQUITY
Retained Earnings -$858.8M -$824.9M
YoY Change 14.01% 11.85%
Common Stock $883.8M $882.3M
YoY Change 12.41% 12.4%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $25.06M $57.37M $78.53M
YoY Change
Total Liabilities & Shareholders Equity $123.5M $149.7M $149.7M
YoY Change 2.2% 57.51% 57.51%

Cashflow Statement

Concept 2024 Q1 2023 Q4 2023
OPERATING ACTIVITIES
Net Income -$33.86M -$27.37M -$87.37M
YoY Change 115.5% 62.83% 18.36%
Depreciation, Depletion And Amortization $6.000K $5.000K $100.0K
YoY Change -80.0% -82.76% 0.0%
Cash From Operating Activities -$28.31M -$29.68M -$86.46M
YoY Change 39.54% 78.63% 35.79%
INVESTING ACTIVITIES
Capital Expenditures $21.00K $0.00 $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities $31.00M $12.44M -$44.45M
YoY Change -3955.72% -4.52% -167.16%
Cash From Investing Activities $30.98M $12.44M -$44.45M
YoY Change -3953.11% -4.52% -167.16%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $91.42M
YoY Change 234.21%
Debt Paid & Issued, Net $300.0K
YoY Change
Cash From Financing Activities 846.0K -446.0K 134.2M
YoY Change -98.08% 159.14%
NET CHANGE
Cash From Operating Activities -28.31M -29.68M -86.46M
Cash From Investing Activities 30.98M 12.44M -44.45M
Cash From Financing Activities 846.0K -446.0K 134.2M
Net Change In Cash 3.518M -17.69M 3.287M
YoY Change -84.68% 392.65% -93.95%
FREE CASH FLOW
Cash From Operating Activities -$28.31M -$29.68M -$86.46M
Capital Expenditures $21.00K $0.00 $0.00
Free Cash Flow -$28.33M -$29.68M -$86.46M
YoY Change 78.63% 35.79%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.93
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-4.57
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-4.90
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
22054000
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
16138000
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
14535000
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2023 dei Entity Central Index Key
EntityCentralIndexKey
0001526119
CY2023 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2023 dei Amendment Flag
AmendmentFlag
false
CY2023 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2023 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2023 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2023 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
25281000
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
16712000
CY2023Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2023 dei Document Type
DocumentType
10-K
CY2023 dei Document Annual Report
DocumentAnnualReport
true
CY2023 dei Document Period End Date
DocumentPeriodEndDate
2023-12-31
CY2023 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023 dei Document Transition Report
DocumentTransitionReport
false
CY2023 dei Entity File Number
EntityFileNumber
001-35403
CY2023 dei Entity Registrant Name
EntityRegistrantName
Verastem, Inc.
CY2023 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023Q4 vstm Deferred Liabilities
DeferredLiabilities
-327000
CY2022Q4 vstm Deferred Liabilities
DeferredLiabilities
-710000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
941000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
794000
CY2023 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
27-3269467
CY2023 dei Entity Address Address Line1
EntityAddressAddressLine1
117 Kendrick Street, Suite 500
CY2023 dei Entity Address City Or Town
EntityAddressCityOrTown
Needham
CY2023 dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2023 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02494
CY2023 dei City Area Code
CityAreaCode
781
CY2023 dei Local Phone Number
LocalPhoneNumber
292-4200
CY2023 dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value
CY2023 dei Trading Symbol
TradingSymbol
VSTM
CY2023 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2023 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2023 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023 dei Entity Small Business
EntitySmallBusiness
true
CY2023 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2023 dei Document Fin Stmt Error Correction Flag
DocumentFinStmtErrorCorrectionFlag
false
CY2023 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Public Float
EntityPublicFloat
186689509
CY2024Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
25295495
CY2023 dei Auditor Firm
AuditorFirmId
42
CY2023 dei Auditor Name
AuditorName
Ernst & Young LLP
CY2023 dei Auditor Location
AuditorLocation
Boston, Massachusetts
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
77909000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
74933000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
59220000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
12961000
CY2022Q4 us-gaap Accounts Receivable Net
AccountsReceivableNet
31000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6553000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4945000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
143682000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
92870000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
37000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
92000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1171000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1789000
CY2023Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
241000
CY2022Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
241000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
4587000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
58000
CY2023Q4 us-gaap Assets
Assets
149718000
CY2022Q4 us-gaap Assets
Assets
95050000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
7184000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4901000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
17928000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
14983000
CY2022Q4 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
275000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
26380000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
21663000
CY2023Q4 us-gaap Secured Long Term Debt
SecuredLongTermDebt
40086000
CY2022Q4 us-gaap Secured Long Term Debt
SecuredLongTermDebt
24526000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
530000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1470000
CY2023Q4 vstm Preferred Stock Tranche Liability
PreferredStockTrancheLiability
4189000
CY2023Q4 us-gaap Liabilities
Liabilities
71185000
CY2022Q4 us-gaap Liabilities
Liabilities
47659000
CY2023Q4 us-gaap Convertible Preferred Stock Nonredeemable Or Redeemable Issuer Option Value
ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue
21159000
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
25281000
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
16712000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
3000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
2000
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
882248000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
784912000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
13000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-824890000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-737523000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
57374000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
47391000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
149718000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
95050000
CY2022 us-gaap Revenues
Revenues
2596000
CY2021 us-gaap Revenues
Revenues
2053000
CY2023 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
61356000
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
50558000
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
39347000
CY2023 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
30728000
CY2022 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
24975000
CY2021 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
24115000
CY2023 us-gaap Costs And Expenses
CostsAndExpenses
92084000
CY2022 us-gaap Costs And Expenses
CostsAndExpenses
75533000
CY2021 us-gaap Costs And Expenses
CostsAndExpenses
63462000
CY2023 us-gaap Operating Income Loss
OperatingIncomeLoss
-92084000
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-72937000
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-61409000
CY2023 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-109000
CY2022 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
47000
CY2023 us-gaap Investment Income Interest
InvestmentIncomeInterest
6214000
CY2022 us-gaap Investment Income Interest
InvestmentIncomeInterest
1215000
CY2021 us-gaap Investment Income Interest
InvestmentIncomeInterest
181000
CY2023 us-gaap Interest Expense
InterestExpense
4139000
CY2022 us-gaap Interest Expense
InterestExpense
2137000
CY2021 us-gaap Interest Expense
InterestExpense
9972000
CY2023 vstm Income Loss From Preferred Stock Tranche Liability
IncomeLossFromPreferredStockTrancheLiability
2751000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-87367000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-73812000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-71200000
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.96
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-4.57
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-4.90
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
22054000
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
16138000
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
14535000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-87367000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-73812000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-71200000
CY2023 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
13000
CY2022 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-34000
CY2021 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-19000
CY2023 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-87354000
CY2022 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-73846000
CY2021 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-71219000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
115274000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-71200000
CY2021 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-19000
CY2021 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
28000000
CY2021 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
182000
CY2020 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
-90000
CY2021 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
905000
CY2021 vstm Stock Issued During Period Value At Market Transactions
StockIssuedDuringPeriodValueAtMarketTransactions
6796000
CY2021 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7711000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
87559000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-73812000
CY2022 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-34000
CY2022 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
164000
CY2022 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
118000
CY2022 vstm Stock Issued During Period Value At Market Transactions
StockIssuedDuringPeriodValueAtMarketTransactions
27349000
CY2022 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6047000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
47391000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-87367000
CY2023 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
13000
CY2023 vstm Issuance Of Preferred Stock Tranche Liability
IssuanceOfPreferredStockTrancheLiability
6940000
CY2023 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
6351000
CY2023 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
57000
CY2023 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5860000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
57374000
CY2023 us-gaap Profit Loss
ProfitLoss
-87367000
CY2022 us-gaap Profit Loss
ProfitLoss
-73812000
CY2021 us-gaap Profit Loss
ProfitLoss
-71200000
CY2023 us-gaap Depreciation
Depreciation
62000
CY2022 us-gaap Depreciation
Depreciation
118000
CY2021 us-gaap Depreciation
Depreciation
206000
CY2023 vstm Operating Lease Right Of Use Asset And Lease Liability Amortization
OperatingLeaseRightOfUseAssetAndLeaseLiabilityAmortization
-175000
CY2022 vstm Operating Lease Right Of Use Asset And Lease Liability Amortization
OperatingLeaseRightOfUseAssetAndLeaseLiabilityAmortization
-154000
CY2021 vstm Operating Lease Right Of Use Asset And Lease Liability Amortization
OperatingLeaseRightOfUseAssetAndLeaseLiabilityAmortization
-134000
CY2023 us-gaap Share Based Compensation
ShareBasedCompensation
5860000
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
6047000
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
7711000
CY2023 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
-1132000
CY2022 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
228000
CY2021 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
9331000
CY2023 vstm Change In Fair Value Of Of Preferred Stock Tranche Liability
ChangeInFairValueOfOfPreferredStockTrancheLiability
-2751000
CY2023 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-31000
CY2022 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-485000
CY2021 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
277000
CY2023 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
5826000
CY2022 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-744000
CY2021 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1558000
CY2023 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2283000
CY2022 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2599000
CY2021 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
623000
CY2023 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
2938000
CY2022 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-638000
CY2021 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
1796000
CY2023 us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
-383000
CY2022 us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
710000
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-86460000
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-63673000
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-53502000
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
196000
CY2023 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
96447000
CY2022 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
17815000
CY2021 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
86442000
CY2023 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
52000000
CY2022 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
84000000
CY2021 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
86725000
CY2023 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-44447000
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
66185000
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
87000
CY2023 us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
28099000
CY2023 us-gaap Proceeds From Issuance Of Secured Debt
ProceedsFromIssuanceOfSecuredDebt
14918000
CY2022 us-gaap Proceeds From Issuance Of Secured Debt
ProceedsFromIssuanceOfSecuredDebt
24148000
CY2023 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
300000
CY2023 vstm Proceeds From Insurance Premium Financing
ProceedsFromInsurancePremiumFinancing
1430000
CY2023 vstm Payments On Insurance Premium Financing
PaymentsOnInsurancePremiumFinancing
1430000
CY2023 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
57000
CY2022 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
282000
CY2021 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1087000
CY2021 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
925000
CY2023 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
91420000
CY2022 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
27354000
CY2021 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
6723000
CY2023 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
134194000
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
51784000
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
6885000
CY2023 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
3287000
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
54296000
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-46530000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
75789000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
21493000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
68023000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
79076000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
75789000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
21493000
CY2023 us-gaap Interest Paid Net
InterestPaidNet
3361000
CY2022 us-gaap Interest Paid Net
InterestPaidNet
1536000
CY2021 us-gaap Interest Paid Net
InterestPaidNet
1007000
CY2023 vstm Issuance Of Preferred Stock Tranche Liability
IssuanceOfPreferredStockTrancheLiability
6940000
CY2021 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
28000000
CY2023 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
7000
CY2023 us-gaap Nature Of Operations
NatureOfOperations
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1. Nature of business</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Verastem, Inc. (the “Company”)<span style="background:#ffffff;"> is a late-stage development biopharmaceutical company, with an ongoing registration directed trial, committed to advancing new medicines for patients battling cancer. The Company’s pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span>The Company’s most advanced product candidates, avutometinib and defactinib, are being investigated in both preclinical and clinical studies for the treatment of various solid tumors, including, but not limited to low-grade serous ovarian cancer (“LGSOC”), non-small cell lung cancer (“NSCLC”), pancreatic cancer, colorectal cancer (“CRC”), and melanoma. The Company believes that avutometinib may be beneficial as a therapeutic as a single agent or when used together in combination with defactinib, other agents, other pathway inhibitors or other current and emerging standard of care treatments in cancers that do not adequately respond to currently available therapies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On September 24, 2018, the Company’s first commercial product, COPIKTRA® (duvelisib), was approved by the U.S. Food and Drug Administration (the “FDA”) for the treatment of adult patients with certain hematologic cancers including relapsed or refractory chronic lymphocytic leukemia/ small lymphocytic lymphoma after at least two prior therapies and relapsed or refractory follicular lymphoma after at least two prior systemic therapies. On August 10, 2020, the Company and Secura Bio, Inc. (“Secura”) entered into an asset purchase agreement (“Secura APA”). Pursuant to the Secura APA, the Company sold to Secura its exclusive worldwide license, including certain related assets for the research, development, commercialization, and manufacture in oncology indications of products containing COPIKTRA (duvelisib). The transaction closed on September 30, 2020. Refer to <i style="font-style:italic;">Note 13. License, collaboration and commercial agreements</i> for a detailed discussion of the Secura APA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The consolidated financial statements include the accounts of Verastem Securities Company and Verastem Europe GmbH, wholly-owned subsidiaries of the Company. All financial information presented has been consolidated and includes the accounts of the Company and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company is subject to the risks associated with other life science companies, including, but not limited to, possible failure of preclinical testing or clinical trials, competitors developing new technological innovations, inability to obtain marketing approval of the Company’s product candidates, avutometinib and defactinib, market acceptance and commercial success of the Company’s product candidates, avutometinib and defactinib, following receipt of regulatory approval, and, protection of proprietary technology and the continued ability to obtain adequate financing to fund the Company’s future operations. If the Company does not obtain marketing approval and successfully commercialize its product candidates, avutometinib and defactinib, following regulatory approval, it will be unable to generate product revenue or achieve profitability and may need to raise additional capital.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2023, the Company had cash, cash equivalents, and investments of $137.1 million. In accordance with applicable accounting standards, the Company evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern within 12 months after the date of the issuance of these consolidated financial statements. The Company anticipates operating losses may continue for the foreseeable future since the Company does not yet have regulatory approval to sell any of its product candidates, and the Company continues to incur operating costs to execute its strategic plan, including costs related to research and development of its product candidates and commercial readiness activities.  These conditions raise substantial doubt about the Company’s ability to continue as a going concern for 12 months after the date the consolidated financial statements are issued.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company expects to finance its operations with its existing cash, cash equivalents and investments, through potential future milestones and royalties received pursuant to the Secura APA, through the loan and security agreement with Oxford Finance LLC (“Oxford”), or through other strategic financing opportunities that could include, but are not limited to collaboration agreements, future offerings of its equity, or the incurrence of debt. However, given the risk associated with these potential strategic or financing opportunities, they are not deemed probable for purposes of the going concern assessment. If the Company fails to obtain additional future capital, it may be unable to complete its planned preclinical studies and clinical trials and obtain approval of certain </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">investigational product candidates from the FDA or foreign regulatory authorities.  Therefore, there is substantial doubt about the Company’s ability to continue as a going concern.  </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;margin:0pt;"><b style="font-weight:bold;">Reverse Stock Split</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;padding-bottom:12pt;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="font-size:10pt;">On May 30, 2023, the Company filed a Certificate of Amendment to the Company’s Restated Certificate of Incorporation, as amended to date, with the Secretary of State of the State of Delaware to effect a reverse stock split of the Company’s issued and outstanding common stock, par value </span><span style="font-size:10pt;">$0.0001</span><span style="font-size:10pt;"> at a ratio of </span><span style="-sec-ix-hidden:Hidden_TYEnAG_KWEmpUHmyPlVVQQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1-for-12</span></span><span style="font-size:10pt;"> (the “Reverse Stock Split”), as authorized at the Company’s 2023 annual meeting of stockholders held on May 15, 2023. The Company effected the Reverse Stock Split on May 31, 2023. No fractional shares were issued in connection with the Reverse Stock Split. Stockholders who otherwise were entitled to a fractional share of common stock were entitled to receive a price equal to the closing price of the common stock on the Nasdaq Capital Market on the date immediately preceding the Reverse Stock Split, as adjusted by the ratio of </span><span style="-sec-ix-hidden:Hidden_eZfgELxsUEWkJnswwStjPA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one</span></span><span style="font-size:10pt;"> share of common stock for every 12 shares of common stock, multiplied by the applicable fraction of a share. The number of shares of common stock that the Company is authorized to issue remains at </span><span style="font-size:10pt;">300,000,000</span><span style="font-size:10pt;"> shares and the par value of its common stock remains unchanged at </span><span style="font-size:10pt;">$0.0001</span><span style="font-size:10pt;"> per share.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-top:2pt;text-indent:36pt;background:#ffffff;margin:0pt;">The Company has retroactively restated the share and per share amounts in the consolidated financial statements as of December 31, 2022 and the 12 months ended December 31, 2023, 2022 and 2021, to give retroactive effect to the Reverse Stock Split. Proportionate adjustments were made to the per share exercise price and number of shares of common stock issuable under all outstanding stock options, convertible notes and preferred stock. In addition, proportionate adjustments have been made to the number of shares of common stock issuable upon vesting of the restricted stock units and the number of shares of common stock reserved for the Company’s equity incentive compensation plans. The consolidated statements of convertible preferred stock and stockholders’ equity and balance sheets reflect the impact of the Reverse Stock Split by reclassifying from “common stock” to “additional paid-in capital” in an amount equal to the par value of the decreased shares resulting from the Reverse Stock Split.</p>
CY2023 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Use of estimates</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">The preparation of the Company’s financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. On an ongoing basis, management evaluates its estimates, including but not limited to estimates related to revenue recognition, accrued and prepaid clinical trial expense and other general accruals, stock-based compensation expense and its preferred stock tranche liability. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable. Actual results could differ from such estimates.</p>
CY2023 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2022Q2 vstm Grant Awarded Amount
GrantAwardedAmount
3800000
CY2022Q3 vstm Proceeds From Grants
ProceedsFromGrants
500000
CY2023 vstm Proceeds From Grants
ProceedsFromGrants
2700000
CY2023 vstm Reduction In Research And Development Expense
ReductionInResearchAndDevelopmentExpense
2000000.0
CY2022 vstm Reduction In Research And Development Expense
ReductionInResearchAndDevelopmentExpense
300000
CY2023Q4 vstm Deferred Liabilities
DeferredLiabilities
-300000
CY2022Q4 vstm Deferred Liabilities
DeferredLiabilities
-700000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
77909000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
74933000
CY2023Q4 vstm Restricted Cash Noncurrent And Prepaid Expenses And Other Current Assets
RestrictedCashNoncurrentAndPrepaidExpensesAndOtherCurrentAssets
1167000
CY2022Q4 vstm Restricted Cash Noncurrent And Prepaid Expenses And Other Current Assets
RestrictedCashNoncurrentAndPrepaidExpensesAndOtherCurrentAssets
856000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
79076000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
75789000
CY2023Q4 vstm Short Term Investments Fair Value Disclosure
ShortTermInvestmentsFairValueDisclosure
59220000
CY2023Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
105313000
CY2021 us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
CY2022 us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
CY2023 us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
CY2022Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Number Of Positions
DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
2
CY2023Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Number Of Positions
DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
2
CY2022Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
0
CY2023Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
0
CY2023Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
8896000
CY2023Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
1000
CY2022Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
5964000
CY2022Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
2000
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
13000
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
1000
CY2023Q4 vstm Cash Cash Equivalents Restricted Cash And Short Term Investments Accumulated Gross Unrealized Gain Before Tax
CashCashEquivalentsRestrictedCashAndShortTermInvestmentsAccumulatedGrossUnrealizedGainBeforeTax
13000
CY2023Q4 vstm Cash Cash Equivalents Restricted Cash And Short Term Investments Accumulated Gross Unrealized Loss Before Tax
CashCashEquivalentsRestrictedCashAndShortTermInvestmentsAccumulatedGrossUnrealizedLossBeforeTax
1000
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
2000
CY2021Q4 vstm Cash Cash Equivalents Restricted Cash And Short Term Investments Accumulated Gross Unrealized Gain Before Tax
CashCashEquivalentsRestrictedCashAndShortTermInvestmentsAccumulatedGrossUnrealizedGainBeforeTax
2000
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
2000
CY2021Q4 vstm Cash Cash Equivalents Restricted Cash And Short Term Investments Accumulated Gross Unrealized Loss Before Tax
CashCashEquivalentsRestrictedCashAndShortTermInvestmentsAccumulatedGrossUnrealizedLossBeforeTax
2000
CY2022Q4 vstm Cash Cash Equivalents Restricted Cash And Short Term Investments Accumulated Gross Unrealized Gain Before Tax
CashCashEquivalentsRestrictedCashAndShortTermInvestmentsAccumulatedGrossUnrealizedGainBeforeTax
2000
CY2022Q4 vstm Cash Cash Equivalents Restricted Cash And Short Term Investments Accumulated Gross Unrealized Loss Before Tax
CashCashEquivalentsRestrictedCashAndShortTermInvestmentsAccumulatedGrossUnrealizedLossBeforeTax
2000
CY2023 us-gaap Concentration Risk Credit Risk Financial Instruments Off Balance Sheet Risk
ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRisk
As of December 31, 2023, the Company’s cash, cash equivalents and investments were deposited at four financial institutions and it has no significant off-balance sheet concentrations of credit risk, such as foreign currency exchange contracts, option contracts or other hedging arrangements.
CY2022 vstm Number Of Financial Institutions In Which Cash Cash Equivalents And Investments Were Deposited
NumberOfFinancialInstitutionsInWhichCashCashEquivalentsAndInvestmentsWereDeposited
4
CY2023 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1629000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1622000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1592000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1530000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
37000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
92000
CY2023 us-gaap Depreciation
Depreciation
100000
CY2022 us-gaap Depreciation
Depreciation
100000
CY2021 us-gaap Depreciation
Depreciation
200000
CY2023Q4 vstm Accrued Clinical Trial Expenses Current
AccruedClinicalTrialExpensesCurrent
6518000
CY2022Q4 vstm Accrued Clinical Trial Expenses Current
AccruedClinicalTrialExpensesCurrent
4281000
CY2023Q4 vstm Accrued Contract Manufacturing Expenses Current
AccruedContractManufacturingExpensesCurrent
2010000
CY2022Q4 vstm Accrued Contract Manufacturing Expenses Current
AccruedContractManufacturingExpensesCurrent
3258000
CY2023Q4 vstm Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
1043000
CY2022Q4 vstm Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
996000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4796000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3844000
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
637000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
469000
CY2023Q4 vstm Accrued Consulting Fees Current
AccruedConsultingFeesCurrent
1078000
CY2022Q4 vstm Accrued Consulting Fees Current
AccruedConsultingFeesCurrent
902000
CY2023Q4 us-gaap Interest Payable Current
InterestPayableCurrent
316000
CY2022Q4 us-gaap Interest Payable Current
InterestPayableCurrent
192000
CY2023Q4 vstm Accrued Commercialization Costs Current
AccruedCommercializationCostsCurrent
453000
CY2022Q4 vstm Accrued Commercialization Costs Current
AccruedCommercializationCostsCurrent
148000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1077000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
893000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
17928000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
14983000
CY2023Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
40000000
CY2022Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
25000000
CY2023Q4 vstm Debt Instrument Final Payment Fee
DebtInstrumentFinalPaymentFee
661000
CY2022Q4 vstm Debt Instrument Final Payment Fee
DebtInstrumentFinalPaymentFee
225000
CY2023Q4 us-gaap Debt Instrument Unamortized Discount Premium Net
DebtInstrumentUnamortizedDiscountPremiumNet
575000
CY2022Q4 us-gaap Debt Instrument Unamortized Discount Premium Net
DebtInstrumentUnamortizedDiscountPremiumNet
699000
CY2023Q4 us-gaap Long Term Debt
LongTermDebt
40086000
CY2022Q4 us-gaap Long Term Debt
LongTermDebt
24526000
CY2023 vstm Contractual Interest Expense
ContractualInterestExpense
3472000
CY2022 vstm Contractual Interest Expense
ContractualInterestExpense
1733000
CY2021 vstm Contractual Interest Expense
ContractualInterestExpense
773000
CY2023 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
230000
CY2022 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
179000
CY2021 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
9199000
CY2023 vstm Amortization Of Final Payment Fee
AmortizationOfFinalPaymentFee
437000
CY2022 vstm Amortization Of Final Payment Fee
AmortizationOfFinalPaymentFee
225000
CY2023 us-gaap Interest Expense
InterestExpense
4139000
CY2022 us-gaap Interest Expense
InterestExpense
2137000
CY2021 us-gaap Interest Expense
InterestExpense
9972000
CY2023Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
15000000
CY2023Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
20000000
CY2023Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
5000000
CY2023Q4 vstm Long Term Debt Maturities Aggregate Principal Due
LongTermDebtMaturitiesAggregatePrincipalDue
40000000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1200000
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
1500000
CY2023 us-gaap Operating Lease Cost
OperatingLeaseCost
885000
CY2022 us-gaap Operating Lease Cost
OperatingLeaseCost
885000
CY2021 us-gaap Operating Lease Cost
OperatingLeaseCost
885000
CY2023 us-gaap Lease Cost
LeaseCost
885000
CY2022 us-gaap Lease Cost
LeaseCost
885000
CY2021 us-gaap Lease Cost
LeaseCost
885000
CY2023 us-gaap Operating Lease Payments
OperatingLeasePayments
1060000
CY2022 us-gaap Operating Lease Payments
OperatingLeasePayments
1039000
CY2021 us-gaap Operating Lease Payments
OperatingLeasePayments
1019000
CY2023Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y6M
CY2023Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.146
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1081000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
546000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
1627000
CY2023Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
156000
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
1471000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2023Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
13672000
CY2022Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
4147000
CY2023 vstm Number Of Votes Per Each Share Of Common Stock
NumberOfVotesPerEachShareOfCommonStock
1
CY2023 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5860000
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6047000
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7711000
CY2023 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5900000
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6000000.0
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7700000
CY2023 vstm Number Of Equity Compensation Plans
NumberOfEquityCompensationPlans
2
CY2023 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7557026
CY2022 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2184710
CY2021 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1597222
CY2023 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.2100
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.2100
CY2023 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.0282
CY2022 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.0215
CY2023 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.0441
CY2022 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.0281
CY2023 us-gaap Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent
EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
-0.0098
CY2022 us-gaap Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent
EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
-0.0217
CY2023 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
0.0044
CY2022 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
-0.0008
CY2023 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.2117
CY2022 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.2141
CY2023 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
-0.0431
CY2023 vstm Effective Income Tax Rate Reconciliation Operating Loss Tax Credit Carryforwards Expiration Percent
EffectiveIncomeTaxRateReconciliationOperatingLossTaxCreditCarryforwardsExpirationPercent
-0.0207
CY2022 vstm Effective Income Tax Rate Reconciliation Operating Loss Tax Credit Carryforwards Expiration Percent
EffectiveIncomeTaxRateReconciliationOperatingLossTaxCreditCarryforwardsExpirationPercent
-0.0226
CY2023 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.0014
CY2022 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.0004
CY2023Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
110152000
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
103243000
CY2023Q4 vstm Deferred Tax Assets Capitalized Research And Development
DeferredTaxAssetsCapitalizedResearchAndDevelopment
20356000
CY2022Q4 vstm Deferred Tax Assets Capitalized Research And Development
DeferredTaxAssetsCapitalizedResearchAndDevelopment
11621000
CY2023Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
11192000
CY2022Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
7107000
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
3340000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
3450000
CY2023Q4 vstm Deferred Tax Assets Installment Sale
DeferredTaxAssetsInstallmentSale
6909000
CY2022Q4 vstm Deferred Tax Assets Installment Sale
DeferredTaxAssetsInstallmentSale
7768000
CY2023Q4 vstm Deferred Tax Assets Lease Liability
DeferredTaxAssetsLeaseLiability
311000
CY2022Q4 vstm Deferred Tax Assets Lease Liability
DeferredTaxAssetsLeaseLiability
538000
CY2023Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
346000
CY2022Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
587000
CY2023Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
152606000
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
134314000
CY2023Q4 vstm Deferred Tax Liabilities Right Of Use Asset
DeferredTaxLiabilitiesRightOfUseAsset
248000
CY2022Q4 vstm Deferred Tax Liabilities Right Of Use Asset
DeferredTaxLiabilitiesRightOfUseAsset
425000
CY2022Q4 us-gaap Deferred Tax Liabilities Derivatives
DeferredTaxLiabilitiesDerivatives
4000
CY2022Q4 us-gaap Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
29000
CY2023Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
248000
CY2022Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
458000
CY2023Q4 vstm Deferred Tax Assets Net Of Deferred Tax Liabilities Before Valuation Allowance
DeferredTaxAssetsNetOfDeferredTaxLiabilitiesBeforeValuationAllowance
152358000
CY2022Q4 vstm Deferred Tax Assets Net Of Deferred Tax Liabilities Before Valuation Allowance
DeferredTaxAssetsNetOfDeferredTaxLiabilitiesBeforeValuationAllowance
133856000
CY2023Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
152358000
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
133856000
CY2022Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2023 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
18500000
CY2023Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2023Q4 us-gaap Liability For Uncertain Tax Positions Noncurrent
LiabilityForUncertainTaxPositionsNoncurrent
0
CY2020Q3 vstm Transition Service Agreement Relaxation Term
TransitionServiceAgreementRelaxationTerm
P1Y
us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
800000

Files In Submission

Name View Source Status
0001558370-24-003250-index-headers.html Edgar Link pending
0001558370-24-003250-index.html Edgar Link pending
0001558370-24-003250.txt Edgar Link pending
0001558370-24-003250-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R79.htm Edgar Link pending
R8.htm Edgar Link pending
R80.htm Edgar Link pending
R81.htm Edgar Link pending
R9.htm Edgar Link pending
R9999.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
vstm-20231231.xsd Edgar Link pending
vstm-20231231x10k.htm Edgar Link pending
vstm-20231231x10k003.jpg Edgar Link pending
vstm-20231231x10k004.jpg Edgar Link pending
vstm-20231231xex21d1.htm Edgar Link pending
vstm-20231231xex23d1.htm Edgar Link pending
vstm-20231231xex31d1.htm Edgar Link pending
vstm-20231231xex31d2.htm Edgar Link pending
vstm-20231231xex32d1.htm Edgar Link pending
vstm-20231231xex32d2.htm Edgar Link pending
vstm-20231231xex97d1.htm Edgar Link pending
vstm-20231231xex99d1.htm Edgar Link pending
vstm-20231231xex99d1002.jpg Edgar Link pending
vstm-20231231_cal.xml Edgar Link unprocessable
vstm-20231231_def.xml Edgar Link unprocessable
vstm-20231231_pre.xml Edgar Link unprocessable
vstm-20231231x10k_htm.xml Edgar Link completed
vstm-20231231_lab.xml Edgar Link unprocessable